HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on cardiac care, has announced its participation as a contributing partner in the launch of EXIT-CVD, a European cardiovascular research initiative co-funded by the European Union Innovative Health Initiative and industry partners. The consortium, led by University Medical Center Groningen and Royal Philips, brings together 42 organizations across 17 countries to conduct 22 clinical studies involving more than 14,000 patients, supported by a total budget of 27.6 million euros. This collaboration marks a significant step in advancing cardiac care through innovative technologies and large-scale clinical research.
HeartBeam will lead the HEART-CHECK study, which will evaluate its portable electrocardiogram (ECG) system for early detection and triage of cardiac events in high-risk patients recently discharged following acute coronary syndrome. The study will assess the system's clinical performance and integration into real-world care pathways. This is particularly important because patients discharged after acute coronary syndrome remain at high risk for recurrent cardiac events, and timely detection can be life-saving. By validating its technology in a real-world setting, HeartBeam aims to demonstrate that its portable ECG system can effectively monitor and alert patients and healthcare providers to potential heart issues, potentially reducing hospital readmissions and improving patient outcomes.
The HeartBeam System recently received U.S. Food and Drug Administration Breakthrough Device Designation for at-home heart attack assessment, an application that remains investigational. This designation is granted to devices that have the potential to provide more effective treatment or diagnosis of life-threatening conditions, and it expedites their development and review. HeartBeam's technology is designed to be the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This platform technology is intended for portable devices that can be used wherever the patient is, delivering actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to technology enablement.
The EXIT-CVD consortium and the HEART-CHECK study represent a major investment in cardiovascular research and innovation. By participating in this initiative, HeartBeam gains access to a vast network of researchers and clinical sites, which can accelerate the validation and adoption of its technology. The study's findings could influence clinical guidelines and reimbursement decisions, potentially opening new markets for HeartBeam's products. For investors, this news underscores HeartBeam's commitment to advancing its technology and expanding its clinical evidence base, which is crucial for regulatory approvals and commercial success.
For more information on HeartBeam's technology, refer to the company's Cleared Indications for Use at https://www.heartbeam.com/indications. The latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT. To view the full press release, visit https://ibn.fm/52Qtj. InvestorWire, a specialized communications platform, distributes press releases for companies like HeartBeam. For more information, visit InvestorWire. InvestorWire is part of the Dynamic Brand Portfolio at IBN. Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer.
